CA
AARD

Clearstead Advisors’s Aardvark Therapeutics AARD Stock Holding History

Clearstead Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226 Buy
+39
New +$182 ﹤0.01% 3174

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Clearstead Advisors's AARD Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 39 shares worth $226. The stake represents ﹤0.01% of the portfolio and ranks #3174 among its holdings.

72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Clearstead Advisors held 39 shares of Aardvark Therapeutics worth $226 as of Q2 2026.
  • Aardvark Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3174 holding.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.